Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News & Views
  • Published:

A flanking attack on cancer

Nature Medicine volume 4, pages 13–14 (1998)Cite this article

Solid tumors in mice treated with several cycles of the angiogenesis inhibitor endostatin regress, do not develop drug resistance, and eventually fail to recur.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Folkman, J. What is the evidence that tumors are angiogenesis dependent? J. Natl Cancer Inst. 82, 4–6 (1989).

    Article  Google Scholar 

  2. Rak, J.W., St Croix, D.B. & Kerbel, R.S. Consequences of angiogenesis for tumor progression, metastasis and cancer therapy. Anti-Cancer Drugs 6, 3–18 (1995).

    Article  CAS  Google Scholar 

  3. Skobe, M., Rockwell, P., Vosseler, S. & Fusenig, N.E. Halting angiogenesis suppresses carcinoma cell invasion. Nature Med. 3, 1222–1227 (1997).

    Article  CAS  Google Scholar 

  4. Hanahan, D. & Folkman, J. Parameters and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 86, 353–354 (1996).

    Article  CAS  Google Scholar 

  5. Boehm, T., Folkman, J., Browder, T. & O'Reilly, M.S. Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance. Nature 390, 404–407 (1997).

    Article  CAS  Google Scholar 

  6. O'Reilly, M.S. et al. Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell 88, 277–285 (1997).

    Article  CAS  Google Scholar 

  7. Kerbel, R.S. A cancer therapy resistant to resistance. Nature 290, 335–336 (1997).

    Article  Google Scholar 

  8. Holmgren, L., O'Reilly, M.S. & Folkman, J. Dormancy of micrometastases: Balanced proliferation and apoptosis in the presence of angiogenesis suppression. Nature Med. 1,149–153 (1995).

    Article  CAS  Google Scholar 

  9. O'Reilly, M.S., Holmgren, L., Chen, C. & Folkman, J. Angiostatin induces and sustains tumor dormancy of human primary tumors in mice. Nature Med. 2, 689–692 (1996).

    Article  CAS  Google Scholar 

  10. Schlingemann, R.O. et al. Differential expression of markers for endothelial cells, pericytes, and basal lamina in the microvasculature of tumors and granulation tissue. Am. J. Path. 138, 1335–1347 (1991).

    CAS  PubMed  Google Scholar 

  11. Jain, R.K. Determinants of tumor blood flow: a review Cancer Res. 48, 2264–2658 (1988).

    Google Scholar 

  12. Hanahan, D. Signaling vascular morphogenesis and maintenance. Science 277, 46–50 (1997).

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Biochemistry & Biophysics, Hormone Research Institute, UCSF, San Francisco, California, 94143-0534, USA

    Douglas Hanahan

Authors
  1. Douglas Hanahan
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Hanahan, D. A flanking attack on cancer. Nat Med 4, 13–14 (1998). https://doi.org/10.1038/nm0198-013

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1038/nm0198-013

This article is cited by

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing